← Back
product
ER100
Last discussed Oct 15, 2026
Life Biosciences' partial epigenetic reprogramming gene therapy using OSK Yamanaka factors for eye diseases.
Recently discussed in
OpenAI Bulk-Solves 722 Math Problems, Anthropic’s Cruelty Policy, & Elon’s Quadrillion-Dollar SpaceX
Peter Diamandis · Oct 15, 2026
What creators say
Peter Diamandis
mentioned
"David Sinclair's Life Biosciences got its phase one results back. They had a gene therapy called ER100 which was injecting the OSK genes into the eyes of patients. Two out of the three patients started regaining their eyesight."
More from Peter Diamandis →Keep exploring
Topics
About this data
- ✓45,000+ mentions extracted from real podcast transcripts
- ✓Every quote links to the source episode
- ✓Sponsored mentions are always labeled
- ✓Critical takes are shown, never filtered out
Get an email when a new creator recommends it